Evolution of the Average Target: Black Diamond Therapeutics, Inc.

Evolution of the Target Price: Black Diamond Therapeutics, Inc.

Changes in Analyst Recommendations: Black Diamond Therapeutics, Inc.

76.AackET9llKJVrSncjpg5FZppt-gQOzW9mQy9Zlx31Lw.dJZrWXYRp9QTzEGt4NN0cNUTx4poCgTUqVvESyk-uvZb8F5yaj3V1BDYSg~dd7398e25f6713e6a65fb8df2979a310
17/03 Wedbush Lifts Price Target on Black Diamond Therapeutics to $14 From $13, Keeps Outperform Rating MT
07/25/07 Black Diamond Therapeutics Q2 net loss narrows as costs drop RE
07/25/07 Wedbush Adjusts Black Diamond Therapeutics Price Target to $11 From $16, Maintains Outperform Rating MT
31/24/31 Raymond James Initiates Black Diamond Therapeutics at Outperform MT
16/24/16 HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating MT
08/24/08 Wedbush Adjusts Price Target on Black Diamond Therapeutics to $16 From $10 After Market Confirmation for Drug, Maintains Outperform Rating MT
14/23/14 Piper Sandler Initiates Black Diamond Therapeutics With Overweight Rating, $11 Price Target MT
30/23/30 Stifel Upgrades Black Diamond Therapeutics to Buy From Hold, Adjusts Price Target to $10 From $2 MT
28/23/28 HC Wainwright Upgrades Black Diamond Therapeutics to Buy From Neutral, Price Target is $11 MT
27/23/27 Wedbush Upgrades Black Diamond Therapeutics to Outperform From Neutral, Adjusts Price Target to $10 From $3 MT
13/22/13 Wedbush Lowers Price Target for Black Diamond Therapeutics to $3 From $4, Maintains Neutral Rating MT
01/22/01 Berenberg Bank Adjusts Black Diamond Therapeutics Price Target to $16 From $34, Maintains Buy Rating MT
29/22/29 Wedbush Downgrades Black Diamond Therapeutics to Neutral From Outperform, Citing BDTX-1535 Timeline, Likely BDTX-189 Discontinuation, 'Tough' Financing Environment; PT to $4 From $22 MT
22/22/22 HC Wainwright Downgrades Black Diamond Therapeutics to Neutral From Buy MT
18/22/18 Stifel Adjusts Price Target on Black Diamond Therapeutics to $4 From $10, Reiterates Hold Rating MT
30/21/30 Black Diamond Therapeutics : Stifel Starts Black Diamond Therapeutics at Hold With $10 Price Target MT
18/21/18 Black Diamond Therapeutics : Wedbush Lowers PT for Black Diamond Therapeutics to $22 From $48 Following BDTX-189 Data, Reiterates Outperform Rating MT
17/21/17 Black Diamond Therapeutics : Berenberg Bank Adjusts Black Diamond Therapeutics PT to $34 From $58, Maintains Buy Rating MT
21/21/21 Black Diamond Therapeutics : Wedbush Removes Outperform-Rated Black Diamond Therapeutics From Best Ideas List; Price Target is $48 MT
29/21/29 Black Diamond Therapeutics : Wedbush Adds Outperform-Rated Black Diamond Therapeutics to Best Ideas List; Price Target is $48 MT
26/21/26 Black Diamond Therapeutics : Wedbush Adjusts Price Target on Black Diamond Therapeutics to $48 From $45, Keeps Outperform Rating MT
07/21/07 Black Diamond Therapeutics : Wedbush Starts Black Diamond Therapeutics at Outperform With $45 Price Target MT
24/20/24 Black Diamond Therapeutics : Berenberg Starts Black Diamond Therapeutics at Buy With $58 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+364.04%
+17.13%
- +8.59%
+7.52%
+61.46%
-2.33%
+14.13%
-11.04%
+17.5%
-2.84%
Average +47.42%
Weighted average by Cap. +13.84%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.155USD
Average target price
10.00USD
Spread / Average Target
+364.04%
High Price Target
14.00USD
Spread / Highest target
+549.65%
Low Price Target
8.000USD
Spread / Lowest Target
+271.23%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Wedbush
HC Wainwright
Piper Sandler
Stifel Nicolaus
Berenberg Bank
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.155USD
Average target price
10.00USD
Spread / Average Target
+364.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock
  4. Consensus Black Diamond Therapeutics, Inc.